SCHEMBL4907007

SCHEMBL4907007

Cc1ccc(Cn2c(-c3cccc(-c4cccc(OCC(=O)O)c4)c3)cc(C(F)(F)F)c(C#N)c2=O)c(C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.49
NR1H2 P55055 3/20 0.49
NR1H3 Q13133 3/20 0.49
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
FABP4 P15090 3/20 0.36
FABP5 Q01469 2/20 0.36
TNKS O95271 2/20 0.35
TNKS2 Q9H2K2 2/20 0.35
HPGD P15428 1/20 0.35
MAOB P27338 1/20 0.35
PPARD Q03181 1/20 0.35
CDK8 P49336 1/20 0.35
SLC5A1 P13866 1/20 0.35
GNRHR P30968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4908276 0.96 RXRA (0.53) RXRANR1H2NR1H3CYP3A4CYP2C9
SCHEMBL14214288 0.91 RXRA (0.46) RXRANR1H2NR1H3CYP3A4CYP2C9
SCHEMBL5597903 0.90 RXRA (0.59) RXRANR1H2NR1H3CYP3A4CYP2C9
SCHEMBL4897271 0.88 RXRA (0.54) RXRANR1H2NR1H3KDM4EALDH1A1
SCHEMBL14214337 0.88 RXRA (0.49) RXRANR1H2NR1H3CYP3A4CYP2C9
SCHEMBL5598133 0.87 RXRA (0.59) RXRANR1H2NR1H3KDM4EALDH1A1
SCHEMBL2262770 0.86 NR1H2 (0.53) RXRANR1H2NR1H3CYP3A4CYP2C9
SCHEMBL4901856 0.85 NR1H2 (0.47) RXRANR1H2NR1H3CYP3A4CYP2C9
SCHEMBL4902072 0.84 RXRA (0.46) RXRANR1H2NR1H3CYP2C9CYP2C19
SCHEMBL2264167 0.84 NR1H2 (0.51) RXRANR1H2NR1H3CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US claimed
EP-1773337-A2 MODULATORS OF NUCLEAR RECEPTORS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006025979-A9 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS INC (US) 2006-04-20 WO claimed
WO-2006025979-A2 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS, INC. (US) 2006-03-09 WO claimed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
WO-2006025979-A9 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS INC (US) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119488-A1 Modulators Of Nuclear Receptors NR1H2, NR0B1, NR1H3 RXRA 20/4885NR1H2 1/4885NR1H3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.